Oncology
Clinical research is centered on advanced solid tumours, with a focus on treatment strategies for difficult-to-manage malignancies.
- Solid tumour therapeutics
- Anti-tumour activity
- Combination immunotherapy
The sponsor’s research activity includes evaluation of single-agent and combination approaches in cancer treatment.
Immuno-oncology
Interest extends to therapies that engage the immune system in the control of tumour growth, including use with pembrolizumab.
- Checkpoint inhibitor combinations
- Tumour response assessment
- Immune-based cancer therapy
This area reflects a therapeutic focus on integrating immunotherapy with targeted anti-cancer treatment in solid tumours.
Early clinical development
Research activity includes early-stage evaluation of novel oncology treatments to define their therapeutic profile in patients with cancer.
- Dose optimisation
- Tolerability evaluation
- Recommended treatment selection
The clinical programme is directed toward establishing the therapeutic potential of new agents for advanced malignancy.
Translational cancer medicine
The sponsor’s research landscape includes work that links biological activity with clinical outcomes in oncology.
- Antitumour response
- Combination efficacy
- Clinical activity in refractory disease
This supports investigation of therapies intended for hard-to-treat solid tumours across multiple active study locations.
